---
authors:
- Ebell, Mark H
category: Case Study
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/39172682/
file_path: 2024/08/nirmatrelvirritonavir-does-not-significantly-reduce-symptoms.md
issue: '2'
keywords:
- Humans
- Middle Aged
- Adult
- Ritonavir
- SARS-CoV-2
- COVID-19 Drug Treatment
- Hospitalization
- Female
- Male
- Drug Combinations
last_updated: '2025-07-30'
mesh_terms:
- Humans
- Ritonavir
- Hospitalization
- Male
- Female
- Middle Aged
- Drug Combinations
- COVID-19 Drug Treatment
- Adult
- SARS-CoV-2
- COVID-19 Vaccines
- COVID-19
- Unvaccinated Persons
original_format: PubMed
pages: '201'
patient_population: Adults
peer_reviewed: true
pmid: '39172682'
processed_date: '2025-07-30'
publication_date: '2024-08-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-10'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Nirmatrelvir/Ritonavir Does Not Significantly Reduce Symptoms or Hospitalization
  in Vaccinated High-Risk Patients and Unvaccinated Patients.
topics:
- Family Medicine
volume: '110'
publication_types: &id001
- Journal Article
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '39172682'
  title: Nirmatrelvir/Ritonavir Does Not Significantly Reduce Symptoms or Hospitalization
    in Vaccinated High-Risk Patients and Unvaccinated Patients.
  authors:
  - last_name: Ebell
    fore_name: Mark H
    initials: MH
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '110'
    issue: '2'
  publication_info:
    year: '2024'
    month: 08
    full_date: '2024-08-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: Ritonavir
    major_topic: true
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Hospitalization
    major_topic: true
    qualifiers:
    - qualifier: statistics & numerical data
      major_topic: false
  - descriptor: Male
    major_topic: false
  - descriptor: Female
    major_topic: false
  - descriptor: Middle Aged
    major_topic: false
  - descriptor: Drug Combinations
    major_topic: false
  - descriptor: COVID-19 Drug Treatment
    major_topic: false
  - descriptor: Adult
    major_topic: false
  - descriptor: SARS-CoV-2
    major_topic: false
  - descriptor: COVID-19 Vaccines
    major_topic: false
    qualifiers:
    - qualifier: administration & dosage
      major_topic: false
  - descriptor: COVID-19
    major_topic: false
    qualifiers:
    - qualifier: prevention & control
      major_topic: false
  - descriptor: Unvaccinated Persons
    major_topic: false
  publication_types: *id001
---

# Nirmatrelvir/Ritonavir Does Not Significantly Reduce Symptoms or Hospitalization in Vaccinated High-Risk Patients and Unvaccinated Patients.

**Authors:** Ebell, Mark H

**Published in:** American family physician | Vol. 110, No. 2 | 2024-08-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/39172682/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Humans, Ritonavir, Hospitalization, Male, Female, Middle Aged, Drug Combinations, COVID-19 Drug Treatment, Adult, SARS-CoV-2, COVID-19 Vaccines, COVID-19, Unvaccinated Persons

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/39172682/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
